Vlacho, B, Simarro, FL, Mata-Cases, M, Miravet, S, Escribano-Serrano, J, Asensio, D, Cortes, X, Franch-Nadal, J. Adherence to antidiabetic treatment among patients managed in primary care centres in Spain: the INTENSE study. Primary Care Diabetes. 2022; 16(6)DOI:10.1016/j.pcd.2022.10.004. PMID:36335018. IF:2.900(Q2/5D).

Puig-Jove, C, Julve, J, Castelblanco, E, Julian, MT, Amigo, N, Andersen, HU, Ahluwalia, TS, Rossing, P, Mauricio, D, Jensen, MT, Alonso, N. The novel inflammatory biomarker GlycA and triglyceride-rich lipoproteins are associated with the presence of subclinical myocardial dysfunction in subjects with type 1 diabetes mellitus. Cardiovascular Diabetology. 2022; 21(1)DOI:10.1186/s12933-022-01652-z. PMID:36434633. IF:9.300(Q1/1D).

Das Pradhan, A, Glynn, RJ, Fruchart, JC, MacFadyen, JG, Zaharris, ES, Everett, BM, Campbell, SE, Oshima, R, Amarenco, P, Blom, DJ, Brinton, EA, Eckel, RH, Elam, MB, Felicio, JS, Ginsberg, HN, Goudev, A, Ishibashi, S, Joseph, J, Kodama, T, Koenig, W, Leiter, LA, Lorenzatti, AJ, Mankovsky, B, Marx, N, Nordestgaard, BG, Pall, D, Ray, KK, Santos, RD, Soran, H, Susekov, A, Tendera, M, Yokote, K, Paynter, NP, Buring, JE, Libby, P, Ridker, PM, PEREZ PEREZ, ANTONIO, Prominent Investigators. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. NEW ENGLAND JOURNAL OF MEDICINE. 2022; 387(21)DOI:10.1056/NEJMoa2210645. PMID:36342113. IF:158.500(Q1/1D).

Castelblanco, E, Granado-Casas, M, Hernandez, M, Pinyol, M, Correig, E, Julve, J, Rojo-Lopez, MI, Alonso, N, Avogaro, A, Ortega, E, Mauricio, D. Diabetic retinopathy predicts cardiovascular disease independently of subclinical atherosclerosis in individuals with type 2 diabetes: A prospective cohort study. Frontiers in Cardiovascular Medicine. 2022; 9DOI:10.3389/fcvm.2022.945421. PMID:36407461. IF:3.600(Q2/5D).